Herantis Pharma Oyj

Helsinki Stock Exchange:HRTIS.HE

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Finland

Market Cap

USD 36.26 M

Share Price

USD 1.50

Avg Daily Volume

13,704

Change (1 day)

4.75%

Change (1 year)

-15.29%

Change (YTD)

-4.86%

Herantis Pharma Oyj Revenue for the year ending December 31, 2024: USD 0.00

Herantis Pharma Oyj Revenue is USD 0.00 for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Herantis Pharma Oyj Revenue for the year ending December 31, 2023 was USD 0.00.
Herantis Pharma Oyj Revenue for the year ending December 31, 2022 was USD 0.00.
Herantis Pharma Oyj Revenue for the year ending December 31, 2021 was USD 0.00.
Herantis Pharma Oyj Revenue for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Helsinki Stock Exchange: HRTIS.HE

Herantis Pharma Oyj

CEO	Dr. Antti Vuolanto D.Sc. (Tech)
IPO Date	June 11, 2014
Location	Finland
Headquarters	Bertel Jungin Aukio 1
Employees	11
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.